Study on clinical treatment of 30 cases of acute deep venous thrombosis
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Objective: To analyze the efficacy of the AngioJet thrombus aspiration system combined with catheter-directed thrombolysis (CDT) in treating acute deep venous thrombosis (ADVT). Methods: Thirty patients with ADVT admitted to a tertiary A-grade hospital from January 2020 to March 2021 were randomly assigned to either the CDT group or the AngioJet group, with 15 patients in each group. The CDT group underwent catheterdirected thrombolysis, while the AngioJet group received the treatment with the AngioJet thrombus aspiration system. There were no statistically significant differences between the two groups in terms of gender, age, onset time, or thrombus type (p > .05). Thrombus clearance rates, limb edema resolution rates, total urokinase dosage, thrombolysis duration, and complications were compared between the two groups of patients with ADVT in this study. Results: The AngioJet group demonstrated superior thrombectomy grading in comparison to the CDT group (Z = 2.340, p = .019). The limb edema resolution rate was significantly higher in the AngioJet group (93.33%) than that in the CDT group (53.33%) (p < .05). The thrombolysis duration in the AngioJet group (0.50 ± 0.11 h) was significantly shorter than that in the CDT group (72.14 ± 0.42 h) (p < .05). The urokinase dosage in the AngioJet group (18.51 ± 2.02 × 104 U) was significantly lower than that in the CDT group (85.34 ± 2.75 × 104 U) (p < .05). The incidence of complications in the AngioJet group (13.33%) was lower than that in the CDT group (26.67%), with no statistically significant difference (p > .05). Conclusions: The AngioJet thrombus aspiration system demonstrates superior thrombus clearance efficacy in comparison to CDT in ADVT patients, with shorter thrombolysis duration, reduced urokinase dosage, and favorable clinical safety.
Fields of Study & Subjects
Venous Thromboembolism Diagnosis and Management
Peripheral Artery Disease Management
Acute Ischemic Stroke Management
Publication details
- Journal / source
- Discussion of Clinical Cases
- Volume
- 11
- Issue
- 3
- Pages
- 1–6
- Publication date
- 29 January 2026
- Language
- EN